aluates Reports

$ 0.0

Automative

Global CD19-targeted CAR-T Cell Therapy Market Research Report 2026

Published Date: 2026-01-26

Report Code: QYRE-Auto-24M18293

Global CD19 targeted CAR T Cell Therapy Market Research Report 2024

BUY CHAPTERS

Global CD19-targeted CAR-T Cell Therapy Market Research Report 2026

Code: QYRE-Auto-24M18293

Report

2026-01-26

Pages:109

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

JUVENTAS

Gilead (Yescarta&Tecartus)

Novartis (Kymriah)

Bristol-Myers Squibb (Breyanzi)

FOSUNKite (Yescarta)

Shanghai Yaoming Juno (Carteyva)

Gilead (Yescarta&Tecartus)

CD19-targeted CAR-T Cell Therapy Market Size

The global CD19-targeted CAR-T Cell Therapy market was valued at US$ 3586 million in 2025 and is anticipated to reach US$ 9771 million by 2032, at a CAGR of 15.6% from 2026 to 2032.

CD19-targeted CAR-T Cell Therapy Market

Chimeric antigen receptor (CAR) T-cell therapy is a type of cancer immunotherapy treatment that uses immune cells called T cells that are genetically altered in a lab to enable them in locating in destroying cancer cells more effectively. Currently available CAR-T cell therapy products are divided into CD19 targets and BCMA targets. CD19 is the most common target. CD19 is a protein that is found on the surface of most B - cells, including malignant B - cells in certain types of leukemia and lymphoma.

The North American market for CD19-targeted CAR-T Cell Therapy is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

The Asia-Pacific market for CD19-targeted CAR-T Cell Therapy is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

The global market for CD19-targeted CAR-T Cell Therapy in Lymphoma is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.

Major global companies of CD19-targeted CAR-T Cell Therapy include Gilead (Yescarta&Tecartus), Novartis (Kymriah), Bristol-Myers Squibb (Breyanzi), FOSUNKite (Yescarta), Shanghai Yaoming Juno (Carteyva), Juventas, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.

This report delivers a comprehensive overview of the global CD19-targeted CAR-T Cell Therapy market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding CD19-targeted CAR-T Cell Therapy. The CD19-targeted CAR-T Cell Therapy market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global CD19-targeted CAR-T Cell Therapy market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist CD19-targeted CAR-T Cell Therapy manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of CD19-targeted CAR-T Cell Therapy Market Report

Report Metric	Details
Report Name	CD19-targeted CAR-T Cell Therapy Market
Accounted market size in 2025	US$ 3586 million
Forecasted market size in 2032	US$ 9771 million
CAGR	15.6%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	Yescarta Kymriah Tecartus Others
Segment by Application	Lymphoma Lymphocytic Leukemia
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Gilead (Yescarta&Tecartus), Novartis (Kymriah), Bristol-Myers Squibb (Breyanzi), FOSUNKite (Yescarta), Shanghai Yaoming Juno (Carteyva), Juventas
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for CD19-targeted CAR-T Cell Therapy companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

FAQ for this report

How fast is CD19-targeted CAR-T Cell Therapy Market growing?

Ans: The CD19-targeted CAR-T Cell Therapy Market witnessing a CAGR of 15.6% during the forecast period 2026-2032.

What is the CD19-targeted CAR-T Cell Therapy Market size in 2032?

Ans: The CD19-targeted CAR-T Cell Therapy Market size in 2032 will be US$ 9771 million.

Who are the main players in the CD19-targeted CAR-T Cell Therapy Market report?

Ans: The main players in the CD19-targeted CAR-T Cell Therapy Market are Gilead (Yescarta&Tecartus), Novartis (Kymriah), Bristol-Myers Squibb (Breyanzi), FOSUNKite (Yescarta), Shanghai Yaoming Juno (Carteyva), Juventas

What are the Application segmentation covered in the CD19-targeted CAR-T Cell Therapy Market report?

Ans: The Applications covered in the CD19-targeted CAR-T Cell Therapy Market report are Lymphoma, Lymphocytic Leukemia

What are the Type segmentation covered in the CD19-targeted CAR-T Cell Therapy Market report?

Ans: The Types covered in the CD19-targeted CAR-T Cell Therapy Market report are Yescarta, Kymriah, Tecartus, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global CD19-targeted CAR-T Cell Therapy Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 Yescarta

1.2.3 Kymriah

1.2.4 Tecartus

1.2.5 Others

1.3 Market by Application

1.3.1 Global CD19-targeted CAR-T Cell Therapy Market Growth by Application: 2021 vs 2025 vs 2032

1.3.2 Lymphoma

1.3.3 Lymphocytic Leukemia

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global CD19-targeted CAR-T Cell Therapy Market Perspective (2021–2032)

2.2 Global CD19-targeted CAR-T Cell Therapy Growth Trends by Region

2.2.1 Global CD19-targeted CAR-T Cell Therapy Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 CD19-targeted CAR-T Cell Therapy Historic Market Size by Region (2021–2026)

2.2.3 CD19-targeted CAR-T Cell Therapy Forecasted Market Size by Region (2027–2032)

2.3 CD19-targeted CAR-T Cell Therapy Market Dynamics

2.3.1 CD19-targeted CAR-T Cell Therapy Industry Trends

2.3.2 CD19-targeted CAR-T Cell Therapy Market Drivers

2.3.3 CD19-targeted CAR-T Cell Therapy Market Challenges

2.3.4 CD19-targeted CAR-T Cell Therapy Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top CD19-targeted CAR-T Cell Therapy Players by Revenue

3.1.1 Global Top CD19-targeted CAR-T Cell Therapy Players by Revenue (2021–2026)

3.1.2 Global CD19-targeted CAR-T Cell Therapy Revenue Market Share by Players (2021–2026)

3.2 Global Top CD19-targeted CAR-T Cell Therapy Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by CD19-targeted CAR-T Cell Therapy Revenue

3.4 Global CD19-targeted CAR-T Cell Therapy Market Concentration Ratio

3.4.1 Global CD19-targeted CAR-T Cell Therapy Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by CD19-targeted CAR-T Cell Therapy Revenue in 2025

3.5 Global Key Players of CD19-targeted CAR-T Cell Therapy Head Offices and Areas Served

3.6 Global Key Players of CD19-targeted CAR-T Cell Therapy, Products and Applications

3.7 Global Key Players of CD19-targeted CAR-T Cell Therapy, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4 CD19-targeted CAR-T Cell Therapy Breakdown Data by Type

4.1 Global CD19-targeted CAR-T Cell Therapy Historic Market Size by Type (2021–2026)

4.2 Global CD19-targeted CAR-T Cell Therapy Forecasted Market Size by Type (2027–2032)

5 CD19-targeted CAR-T Cell Therapy Breakdown Data by Application

5.1 Global CD19-targeted CAR-T Cell Therapy Historic Market Size by Application (2021–2026)

5.2 Global CD19-targeted CAR-T Cell Therapy Forecasted Market Size by Application (2027–2032)

6 North America

6.1 North America CD19-targeted CAR-T Cell Therapy Market Size (2021–2032)

6.2 North America CD19-targeted CAR-T Cell Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America CD19-targeted CAR-T Cell Therapy Market Size by Country (2021–2026)

6.4 North America CD19-targeted CAR-T Cell Therapy Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe CD19-targeted CAR-T Cell Therapy Market Size (2021–2032)

7.2 Europe CD19-targeted CAR-T Cell Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe CD19-targeted CAR-T Cell Therapy Market Size by Country (2021–2026)

7.4 Europe CD19-targeted CAR-T Cell Therapy Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific CD19-targeted CAR-T Cell Therapy Market Size (2021–2032)

8.2 Asia-Pacific CD19-targeted CAR-T Cell Therapy Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific CD19-targeted CAR-T Cell Therapy Market Size by Region (2021–2026)

8.4 Asia-Pacific CD19-targeted CAR-T Cell Therapy Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America CD19-targeted CAR-T Cell Therapy Market Size (2021–2032)

9.2 Latin America CD19-targeted CAR-T Cell Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America CD19-targeted CAR-T Cell Therapy Market Size by Country (2021–2026)

9.4 Latin America CD19-targeted CAR-T Cell Therapy Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa CD19-targeted CAR-T Cell Therapy Market Size (2021–2032)

10.2 Middle East & Africa CD19-targeted CAR-T Cell Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa CD19-targeted CAR-T Cell Therapy Market Size by Country (2021–2026)

10.4 Middle East & Africa CD19-targeted CAR-T Cell Therapy Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Gilead (Yescarta&Tecartus)

11.1.1 Gilead (Yescarta&Tecartus) Company Details

11.1.2 Gilead (Yescarta&Tecartus) Business Overview

11.1.3 Gilead (Yescarta&Tecartus) CD19-targeted CAR-T Cell Therapy Introduction

11.1.4 Gilead (Yescarta&Tecartus) Revenue in CD19-targeted CAR-T Cell Therapy Business (2021–2026)

11.1.5 Gilead (Yescarta&Tecartus) Recent Development

11.2 Novartis (Kymriah)

11.2.1 Novartis (Kymriah) Company Details

11.2.2 Novartis (Kymriah) Business Overview

11.2.3 Novartis (Kymriah) CD19-targeted CAR-T Cell Therapy Introduction

11.2.4 Novartis (Kymriah) Revenue in CD19-targeted CAR-T Cell Therapy Business (2021–2026)

11.2.5 Novartis (Kymriah) Recent Development

11.3 Bristol-Myers Squibb (Breyanzi)

11.3.1 Bristol-Myers Squibb (Breyanzi) Company Details

11.3.2 Bristol-Myers Squibb (Breyanzi) Business Overview

11.3.3 Bristol-Myers Squibb (Breyanzi) CD19-targeted CAR-T Cell Therapy Introduction

11.3.4 Bristol-Myers Squibb (Breyanzi) Revenue in CD19-targeted CAR-T Cell Therapy Business (2021–2026)

11.3.5 Bristol-Myers Squibb (Breyanzi) Recent Development

11.4 FOSUNKite (Yescarta)

11.4.1 FOSUNKite (Yescarta) Company Details

11.4.2 FOSUNKite (Yescarta) Business Overview

11.4.3 FOSUNKite (Yescarta) CD19-targeted CAR-T Cell Therapy Introduction

11.4.4 FOSUNKite (Yescarta) Revenue in CD19-targeted CAR-T Cell Therapy Business (2021–2026)

11.4.5 FOSUNKite (Yescarta) Recent Development

11.5 Shanghai Yaoming Juno (Carteyva)

11.5.1 Shanghai Yaoming Juno (Carteyva) Company Details

11.5.2 Shanghai Yaoming Juno (Carteyva) Business Overview

11.5.3 Shanghai Yaoming Juno (Carteyva) CD19-targeted CAR-T Cell Therapy Introduction

11.5.4 Shanghai Yaoming Juno (Carteyva) Revenue in CD19-targeted CAR-T Cell Therapy Business (2021–2026)

11.5.5 Shanghai Yaoming Juno (Carteyva) Recent Development

11.6 Juventas

11.6.1 Juventas Company Details

11.6.2 Juventas Business Overview

11.6.3 Juventas CD19-targeted CAR-T Cell Therapy Introduction

11.6.4 Juventas Revenue in CD19-targeted CAR-T Cell Therapy Business (2021–2026)

11.6.5 Juventas Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

JUVENTAS

Gilead (Yescarta&Tecartus)

Novartis (Kymriah)

Bristol-Myers Squibb (Breyanzi)

FOSUNKite (Yescarta)

Shanghai Yaoming Juno (Carteyva)

Gilead (Yescarta&Tecartus)

List of Tables

Table 1. Global CD19-targeted CAR-T Cell Therapy Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Key Players of Yescarta

Table 3. Key Players of Kymriah

Table 4. Key Players of Tecartus

Table 5. Key Players of Others

Table 6. Global CD19-targeted CAR-T Cell Therapy Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 7. Global CD19-targeted CAR-T Cell Therapy Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 8. Global CD19-targeted CAR-T Cell Therapy Market Size by Region (US$ Million), 2021–2026

Table 9. Global CD19-targeted CAR-T Cell Therapy Market Share by Region (2021–2026)

Table 10. Global CD19-targeted CAR-T Cell Therapy Forecasted Market Size by Region (US$ Million), 2027–2032

Table 11. Global CD19-targeted CAR-T Cell Therapy Market Share by Region (2027–2032)

Table 12. CD19-targeted CAR-T Cell Therapy Market Trends

Table 13. CD19-targeted CAR-T Cell Therapy Market Drivers

Table 14. CD19-targeted CAR-T Cell Therapy Market Challenges

Table 15. CD19-targeted CAR-T Cell Therapy Market Restraints

Table 16. Global CD19-targeted CAR-T Cell Therapy Revenue by Players (US$ Million), 2021–2026

Table 17. Global CD19-targeted CAR-T Cell Therapy Market Share by Players (2021–2026)

Table 18. Global Top CD19-targeted CAR-T Cell Therapy Players by Tier (Tier 1, Tier 2, and Tier 3), based on CD19-targeted CAR-T Cell Therapy Revenue, 2025

Table 19. Ranking of Global Top CD19-targeted CAR-T Cell Therapy Companies by Revenue (US$ Million) in 2025

Table 20. Global 5 Largest Players Market Share by CD19-targeted CAR-T Cell Therapy Revenue (CR5 and HHI), 2021–2026

Table 21. Global Key Players of CD19-targeted CAR-T Cell Therapy, Headquarters and Area Served

Table 22. Global Key Players of CD19-targeted CAR-T Cell Therapy, Products and Applications

Table 23. Global Key Players of CD19-targeted CAR-T Cell Therapy, Date of General Availability (GA)

Table 24. Mergers and Acquisitions, Expansion Plans

Table 25. Global CD19-targeted CAR-T Cell Therapy Market Size by Type (US$ Million), 2021–2026

Table 26. Global CD19-targeted CAR-T Cell Therapy Revenue Market Share by Type (2021–2026)

Table 27. Global CD19-targeted CAR-T Cell Therapy Forecasted Market Size by Type (US$ Million), 2027–2032

Table 28. Global CD19-targeted CAR-T Cell Therapy Revenue Market Share by Type (2027–2032)

Table 29. Global CD19-targeted CAR-T Cell Therapy Market Size by Application (US$ Million), 2021–2026

Table 30. Global CD19-targeted CAR-T Cell Therapy Revenue Market Share by Application (2021–2026)

Table 31. Global CD19-targeted CAR-T Cell Therapy Forecasted Market Size by Application (US$ Million), 2027–2032

Table 32. Global CD19-targeted CAR-T Cell Therapy Revenue Market Share by Application (2027–2032)

Table 33. North America CD19-targeted CAR-T Cell Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 34. North America CD19-targeted CAR-T Cell Therapy Market Size by Country (US$ Million), 2021–2026

Table 35. North America CD19-targeted CAR-T Cell Therapy Market Size by Country (US$ Million), 2027–2032

Table 36. Europe CD19-targeted CAR-T Cell Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 37. Europe CD19-targeted CAR-T Cell Therapy Market Size by Country (US$ Million), 2021–2026

Table 38. Europe CD19-targeted CAR-T Cell Therapy Market Size by Country (US$ Million), 2027–2032

Table 39. Asia-Pacific CD19-targeted CAR-T Cell Therapy Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

Table 40. Asia-Pacific CD19-targeted CAR-T Cell Therapy Market Size by Region (US$ Million), 2021–2026

Table 41. Asia-Pacific CD19-targeted CAR-T Cell Therapy Market Size by Region (US$ Million), 2027–2032

Table 42. Latin America CD19-targeted CAR-T Cell Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 43. Latin America CD19-targeted CAR-T Cell Therapy Market Size by Country (US$ Million), 2021–2026

Table 44. Latin America CD19-targeted CAR-T Cell Therapy Market Size by Country (US$ Million), 2027–2032

Table 45. Middle East & Africa CD19-targeted CAR-T Cell Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 46. Middle East & Africa CD19-targeted CAR-T Cell Therapy Market Size by Country (US$ Million), 2021–2026

Table 47. Middle East & Africa CD19-targeted CAR-T Cell Therapy Market Size by Country (US$ Million), 2027–2032

Table 48. Gilead (Yescarta&Tecartus) Company Details

Table 49. Gilead (Yescarta&Tecartus) Business Overview

Table 50. Gilead (Yescarta&Tecartus) CD19-targeted CAR-T Cell Therapy Product

Table 51. Gilead (Yescarta&Tecartus) Revenue in CD19-targeted CAR-T Cell Therapy Business (US$ Million), 2021–2026

Table 52. Gilead (Yescarta&Tecartus) Recent Development

Table 53. Novartis (Kymriah) Company Details

Table 54. Novartis (Kymriah) Business Overview

Table 55. Novartis (Kymriah) CD19-targeted CAR-T Cell Therapy Product

Table 56. Novartis (Kymriah) Revenue in CD19-targeted CAR-T Cell Therapy Business (US$ Million), 2021–2026

Table 57. Novartis (Kymriah) Recent Development

Table 58. Bristol-Myers Squibb (Breyanzi) Company Details

Table 59. Bristol-Myers Squibb (Breyanzi) Business Overview

Table 60. Bristol-Myers Squibb (Breyanzi) CD19-targeted CAR-T Cell Therapy Product

Table 61. Bristol-Myers Squibb (Breyanzi) Revenue in CD19-targeted CAR-T Cell Therapy Business (US$ Million), 2021–2026

Table 62. Bristol-Myers Squibb (Breyanzi) Recent Development

Table 63. FOSUNKite (Yescarta) Company Details

Table 64. FOSUNKite (Yescarta) Business Overview

Table 65. FOSUNKite (Yescarta) CD19-targeted CAR-T Cell Therapy Product

Table 66. FOSUNKite (Yescarta) Revenue in CD19-targeted CAR-T Cell Therapy Business (US$ Million), 2021–2026

Table 67. FOSUNKite (Yescarta) Recent Development

Table 68. Shanghai Yaoming Juno (Carteyva) Company Details

Table 69. Shanghai Yaoming Juno (Carteyva) Business Overview

Table 70. Shanghai Yaoming Juno (Carteyva) CD19-targeted CAR-T Cell Therapy Product

Table 71. Shanghai Yaoming Juno (Carteyva) Revenue in CD19-targeted CAR-T Cell Therapy Business (US$ Million), 2021–2026

Table 72. Shanghai Yaoming Juno (Carteyva) Recent Development

Table 73. Juventas Company Details

Table 74. Juventas Business Overview

Table 75. Juventas CD19-targeted CAR-T Cell Therapy Product

Table 76. Juventas Revenue in CD19-targeted CAR-T Cell Therapy Business (US$ Million), 2021–2026

Table 77. Juventas Recent Development

Table 78. Research Programs/Design for This Report

Table 79. Key Data Information from Secondary Sources

Table 80. Key Data Information from Primary Sources

Table 81. Authors List of This Report

List of Figures

Figure 1. CD19-targeted CAR-T Cell Therapy Picture

Figure 2. Global CD19-targeted CAR-T Cell Therapy Market Size Comparison by Type (US$ Million), 2021–2032

Figure 3. Global CD19-targeted CAR-T Cell Therapy Market Share by Type: 2025 vs 2032

Figure 4. Yescarta Features

Figure 5. Kymriah Features

Figure 6. Tecartus Features

Figure 7. Others Features

Figure 8. Global CD19-targeted CAR-T Cell Therapy Market Size by Application (US$ Million), 2021–2032

Figure 9. Global CD19-targeted CAR-T Cell Therapy Market Share by Application: 2025 vs 2032

Figure 10. Lymphoma Case Studies

Figure 11. Lymphocytic Leukemia Case Studies

Figure 12. CD19-targeted CAR-T Cell Therapy Report Years Considered

Figure 13. Global CD19-targeted CAR-T Cell Therapy Market Size (US$ Million), Year-over-Year: 2021–2032

Figure 14. Global CD19-targeted CAR-T Cell Therapy Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 15. Global CD19-targeted CAR-T Cell Therapy Market Share by Region: 2025 vs 2032

Figure 16. Global CD19-targeted CAR-T Cell Therapy Market Share by Players in 2025

Figure 17. Global CD19-targeted CAR-T Cell Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 18. The Top 10 and 5 Players Market Share by CD19-targeted CAR-T Cell Therapy Revenue in 2025

Figure 19. North America CD19-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 20. North America CD19-targeted CAR-T Cell Therapy Market Share by Country (2021–2032)

Figure 21. United States CD19-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 22. Canada CD19-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 23. Europe CD19-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 24. Europe CD19-targeted CAR-T Cell Therapy Market Share by Country (2021–2032)

Figure 25. Germany CD19-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 26. France CD19-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 27. U.K. CD19-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 28. Italy CD19-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 29. Russia CD19-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 30. Ireland CD19-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 31. Asia-Pacific CD19-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 32. Asia-Pacific CD19-targeted CAR-T Cell Therapy Market Share by Region (2021–2032)

Figure 33. China CD19-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 34. Japan CD19-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 35. South Korea CD19-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 36. Southeast Asia CD19-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 37. India CD19-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 38. Australia & New Zealand CD19-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 39. Latin America CD19-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 40. Latin America CD19-targeted CAR-T Cell Therapy Market Share by Country (2021–2032)

Figure 41. Mexico CD19-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 42. Brazil CD19-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 43. Middle East & Africa CD19-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 44. Middle East & Africa CD19-targeted CAR-T Cell Therapy Market Share by Country (2021–2032)

Figure 45. Israel CD19-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 46. Saudi Arabia CD19-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 47. UAE CD19-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032

Figure 48. Gilead (Yescarta&Tecartus) Revenue Growth Rate in CD19-targeted CAR-T Cell Therapy Business (2021–2026)

Figure 49. Novartis (Kymriah) Revenue Growth Rate in CD19-targeted CAR-T Cell Therapy Business (2021–2026)

Figure 50. Bristol-Myers Squibb (Breyanzi) Revenue Growth Rate in CD19-targeted CAR-T Cell Therapy Business (2021–2026)

Figure 51. FOSUNKite (Yescarta) Revenue Growth Rate in CD19-targeted CAR-T Cell Therapy Business (2021–2026)

Figure 52. Shanghai Yaoming Juno (Carteyva) Revenue Growth Rate in CD19-targeted CAR-T Cell Therapy Business (2021–2026)

Figure 53. Juventas Revenue Growth Rate in CD19-targeted CAR-T Cell Therapy Business (2021–2026)

Figure 54. Bottom-up and Top-down Approaches for This Report

Figure 55. Data Triangulation

Figure 56. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global CAR T Cell Therapy Market Research Report 2025

Global CAR T Cell Service Market Research Report 2024

Global CAR T cell Therapy Drug Market Research Report 2025

Global Drug based on CAR T Cell Market Research Report 2025

Global CAR T Cell Therapy Agents Market Research Report 2025

Global Drugs Based on CAR T cell Market Research Report 2025

CAR T Cellular Immunotherapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

CAR T Cell Based Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global CAR T Therapy for Hematological Cancer Market Research Report 2024

Cancer Drug based on CAR T Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Autologous CAR T Cell Therapy Market Research Report 2024

Global T Cell Immunotherapy Market Research Report 2025

Global CAR T Cell Manufacturing Service Market Research Report 2024

Global CAR T Cell Development Service Market Research Report 2024

Global CAR T Cell Immunotherapy Market Insights Forecast to 2030

Chimeric Antigen Receptor CAR T Cell Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Gene Modifying Immunotherapy for Blood Cancer Market Insights Forecast to 2030

Global TCR T Cellular Immunotherapy Market Research Report 2024

CAR T Cell Immunotherapies for Cancer Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions